<DOC>
	<DOCNO>NCT00096382</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide fludarabine , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Biological therapy , cellular adoptive immunotherapy , work different way stimulate immune system stop tumor cell grow . Autologous stem cell transplant may able replace immune cell destroy chemotherapy radiation therapy . Interleukin-2 may stimulate person 's lymphocyte kill tumor cell . Combining chemotherapy , radiation therapy , biological therapy may kill tumor cell . PURPOSE : This phase II trial study well give cyclophosphamide fludarabine together radiation therapy follow cellular adoptive immunotherapy , autologous stem cell transplant , interleukin-2 work treat patient metastatic melanoma .</brief_summary>
	<brief_title>Cyclophosphamide , Fludarabine , Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy , Autologous Stem Cell Transplantation , Interleukin-2 Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete clinical tumor regression patient metastatic melanoma treat myeloablative lymphoid-depleting preparative regimen comprise cyclophosphamide , fludarabine , total body irradiation follow autologous tumor-reactive tumor-infiltrating lymphocyte infusion , autologous CD34+ stem cell transplantation , low-dose high-dose interleukin-2 . - Evaluate safety regimen patient . Secondary - Determine survival infuse lymphocyte analyze sequence variable region T-cell receptor flow cytometry patient treat regimen . OUTLINE : - Autologous stem cell collection : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) twice daily 8 day . Beginning day 5 G-CSF , patient undergo apheresis daily 3 day . Patients may receive 1 additional course G-CSF apheresis use stem cell store prior stem cell harvest order obtain adequate number cell . - Lymphocyte-depleting myeloablative preparative regimen : Patients receive cyclophosphamide intravenous ( IV ) 1 hour day -5 -6 fludarabine IV 15-30 minute day -6 -2 . Patients also undergo total body irradiation day -1 . - Autologous lymphocyte infusion : Patients receive autologous tumor-reactive tumor-infiltrating lymphocyte IV 20-30 minute day 0* follow G-CSF SC daily blood count recover . - Autologous stem cell transplantation : Patients receive autologous CD34+ stem cell IV day 2 . - Interleukin therapy : Patients assign 1 2 cohort , depend whether receive prior high-dose interleukin-2 ( IL-2 ) . - Cohort 1 ( patient receive prior high-dose IL-2 ) : Beginning day 0* , patient receive high-dose IL-2 IV 15 minute 3 time daily 5 day ( maximum 15 dos ) . - Cohort 3 ( patient receive prior high-dose IL-2 ) : Patients receive treatment cohort 1 . NOTE : *Day 0 1-4 day last dose fludarabine . Patients evaluate 4-6 week . PROJECTED ACCRUAL : A total 116 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic melanoma Measurable disease Resected stable brain metastasis allow PATIENT CHARACTERISTICS : Age 18 Performance status Eastern Cooperative Oncology Group ( ECOG ) 01 Life expectancy At least 3 month Hematopoietic See Immunologic Absolute neutrophil count &gt; 1,000/mm^3 ( without support filgrastim [ GCSF ] ) Platelet count &gt; 100,000/mm^3 Hemoglobin ≥ 8 g/dL ( transfusion allow ) No coagulation disorder Hepatic Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 3 time upper limit normal Bilirubin ≤ 2 mg/dL ( &lt; 3 mg/dL patient Gilbert 's syndrome ) No hepatitis B C Renal Creatinine ≤ 1.6 mg/dL Cardiovascular Left ventricular ejection fraction ( LVEF ) ≥ 45 % cardiac stress test* No active major cardiovascular illness evidence stress thallium comparable test No myocardial infarction No cardiac arrhythmia NOTE : *For patient ≥ 50 year age receive highdose interleukin2 ( IL2 ) OR patient history electrocardiogram ( EKG ) abnormality , symptom cardiac ischemia , arrhythmias Pulmonary Forced expiratory volume 1 ( FEV_1 ) ≥ 60 % predict pulmonary function test patient prolong history cigarette smoking symptom respiratory dysfunction* No active major respiratory illness No obstructive restrictive pulmonary disease NOTE : *For patient receive highdose IL2 Immunologic No active major immunologic illness No active systemic infection No primary secondary immunodeficiency Fully recover immune competence prior chemotherapy radiotherapy evidence follow : Absolute neutrophil count &gt; 1,000/mm^3 No opportunistic infection Human Immunodeficiency virus ( HIV ) negative EpsteinBarr virus positive Other Not pregnant nursing Fertile patient must use effective contraception 4 month study treatment PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy At least 6 week since prior nitrosourea therapy No prior cyclophosphamide fludarabine part preparative regimen National Cancer Institute ( NCI ) Surgery Branch adoptive cell therapy study unless sufficient number CD34+ stem cell ( 2 x10^6/kg patient weight ) obtain prior administration chemotherapy Endocrine therapy No concurrent systemic steroid therapy Radiotherapy Not specify Surgery See Disease Characteristics Prior minor surgery within past 3 week allow recover Other Recovered prior therapy At least 30 day since prior systemic therapy No concurrent experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>